3PC-004 Insulin eye drop formulation: effectiveness, safety and patient satisfaction. (23rd March 2022)

• Record Type: Journal Article
• Authors: Iglesias Rodrigo, M; Salazar Gonzalez, F; Pardo Pastor, J; Meca Casasnovas, N; Sebastián Carrasco, C; Garreta Fontelles, G; Nicolás Picó, J
• Is Part Of: European journal of hospital pharmacy. Volume 29(2022)Supplement 1
• Page Start: A15
• Page End: A15
• Publication Date: 2022-03-23
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2022-eahp.31
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background and importance: Recently, the insulin eye drops formulation 1 IU/mL has been included in the Pharmacotherapeutic Guide. Recent studies demonstrate its efficacy and safety in the treatment of keratitis and dry eye. Aim and objectives: To analyse the patient profile and describe the characteristics of insulin eye drops treatment, as well as its effectiveness, tolerance and patient satisfaction. Material and methods: Retrospective observational study in a tertiary hospital. All patients treated with insulin eye drops during the period January–September 2021 were included. The variables collected were: demographics, indication, duration of treatment, line of treatment, clinical response and adverse effects (both described in the clinical history) and patient satisfaction (using the 'Treatment Satisfaction Questionnaire for Medication' version 1.4: 14 questions, distributed in four domains: effectiveness, side effects, convenience and overall satisfaction). A descriptive statistical analysis was performed with measures of central tendency and dispersion for quantitative variables (mean and standard deviation (SD)) and absolute frequencies for categorical variables. Results: A total of 34 patients treated with insulin eye drops 1 UI/mL were included. The mean age was 58.89 (SD 15.79) years. A total of 47.10% were women. 35.29% were diagnosed with non-herpetic keratitis, 20.59% with herpetic keratitis, 17.65% with corneal erosion, 14.71% with dry eye, 8.82% with pterygium and 2.94% others. The duration of treatment was 120.01 (SD 43.81) days. A total of 17.59% were treated in the fourth or successive lines, 17.65% in the third, 8.82% in the second and 2.94% in the first. Almost all (91.18%) the patients responded to treatment and 8.82% of patients showed toxicity (conjunctival hyperemia and ocular pain). Patients were satisfied or betterrior with the treatment: 91.17% in terms of effectiveness, 8.53% adverse effects, 88.23% convenience and 94.12% overall satisfaction. Conclusion and relevance: The insulin eye drops formulation 1 IU/mL is a good therapeutic alternative as a rescue treatment in patients refractory to the usual treatments. The preparation, by the pharmacist, of formulas allows coverage of possible therapeutic gaps in the treatment of herpetic and non-herpetic keratitis. References and/or acknowledgements: Conflict of interest: No conflict of interest